Loss of TCR-beta F1 and/or EZRIN expression is associated with unfavorable prognosis in nodal peripheral T-cell lymphomas

S. M. Rodriguez-Pinilla, M. E C Sanchez, J. Rodriguez, J. F. Garcia, B. Sanchez-Espiridion, L. F. Lamana, G. Sosa, J. C. Rivero, J. Menarguez, I. B. Gomez, F. I. Camacho, P. R. Guillen, C. P S Orduna, G. Rodriguez, C. Barrionuevo, R. Franco, M. Mollejo, J. F. Marco, R. D. De Otazu, M. A. Piris

Research output: Contribution to journalArticlepeer-review

Abstract

Nodal peripheral T-cell lymphoma (nodal PTCL) has an unfavorable prognosis, and specific pathogenic alterations have not been fully identified. The biological and clinical relevance of the expression of CD30/T-cell receptor (TCR) genes is a topic under active investigation. One-hundred and ninety-three consecutive nodal PTCLs (89 angioimmunoblastic T-cell lymphomas (AITL) and 104 PTCL-unspecified (PTCL-not otherwise specified (NOS)) cases) were analyzed for the immunohistochemical expression of 19 molecules, involving TCR/CD30 pathways and the associations with standard prognostic indices. Mutually exclusive expression was found between CD3 and TCR-beta F1 with CD30 expression. Taking all PTCL cases together, logistic regression identified a biological score (BS) including TCR molecules (TCR-beta F1 and EZRIN) that separates two subgroups of patients with a median survival of 34.57 and 5.20 months (P

Original languageEnglish
Article numbere111
JournalBlood Cancer Journal
Volume3
Issue number4
DOIs
Publication statusPublished - Apr 2013

Keywords

  • BLIMP1
  • EZRIN
  • JUNB
  • T-cell lymphoma
  • TCR-beta F1

ASJC Scopus subject areas

  • Oncology
  • Hematology

Fingerprint Dive into the research topics of 'Loss of TCR-beta F1 and/or EZRIN expression is associated with unfavorable prognosis in nodal peripheral T-cell lymphomas'. Together they form a unique fingerprint.

Cite this